GH Research PLC (NASDAQ:GHRS) Sees Large Growth in Short Interest

GH Research PLC (NASDAQ:GHRS) was the target of a significant increase in short interest during the month of December. As of December 31st, there was short interest totalling 2,280,000 shares, an increase of 11.8% from the December 15th total of 2,040,000 shares. Currently, 7.5% of the shares of the stock are sold short. Based on an average daily volume of 72,900 shares, the short-interest ratio is currently 31.3 days.

Institutional Investors Weigh In On GH Research

An institutional investor recently raised its position in GH Research stock. RA Capital Management L.P. increased its position in shares of GH Research PLC (NASDAQ:GHRS) by 1.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,686,689 shares of the company’s stock after acquiring an additional 85,000 shares during the period. RA Capital Management L.P. owned about 12.85% of GH Research worth $44,734,000 as of its most recent filing with the Securities and Exchange Commission. 56.90% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages recently issued reports on GHRS. Canaccord Genuity Group decreased their target price on GH Research from $31.00 to $28.00 and set a “buy” rating on the stock in a report on Monday, November 18th. HC Wainwright reissued a “buy” rating and issued a $40.00 price target on shares of GH Research in a research note on Friday, January 10th.

GH Research Price Performance

NASDAQ GHRS opened at $8.88 on Monday. The company has a 50 day simple moving average of $8.45 and a 200-day simple moving average of $9.05. GH Research has a 52-week low of $5.50 and a 52-week high of $14.99.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).